Trials / Completed
CompletedNCT05133830
Linerixibat and Obeticholic Acid Drug Interaction Study in Healthy Adult Participants
A Two-part, Phase 1, Open-label, Randomized, Parallel-arm, Fixed Sequence, Drug-drug Interaction Study to Investigate the Effect of Linerixibat on Plasma Concentrations of Obeticholic Acid and Conjugates in Healthy Adult Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 52 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
This study aims to investigate the effect of linerixibat on plasma concentrations of obeticholic acid (OCA) and its conjugates in healthy adult participants to inform the potential for drug interaction with coadministration of linerixibat and OCA.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Obeticholic acid | OCA will be administered |
| DRUG | Linerixibat | Linerixibat will be administered |
Timeline
- Start date
- 2021-11-23
- Primary completion
- 2022-05-31
- Completion
- 2022-05-31
- First posted
- 2021-11-24
- Last updated
- 2022-11-08
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05133830. Inclusion in this directory is not an endorsement.